Liberate Bio Announces Presentation to Update on Advancements on their RAPTOR LNP Platform
May 16 2024 - 7:00AM
Business Wire
Liberate Bio, Inc., a company delivering genetic medicines that
transcend liver-based limitations, announced an oral presentation
demonstrating the success of their RAPTOR™ screening platform and
its first generation of extrahepatic lipid nanoparticles at the
Oligonucleotide and Peptide Therapeutics 2024 (TIDES) being held
May 14-17, 2024, in Boston, Massachusetts.
“We are excited to demonstrate both the establishment of our
Rapid Particle Optimizer (RAPTOR™) platform and the first results
from our high-throughput screening in the platform at TIDES,” said
Walter R. Strapps, Ph.D., Chief Scientific Officer of Liberate.
“The presentation demonstrates our ability to rapidly screen a
diverse lipid library, designed rationally and by generative
artificial intelligence, directly in non-human primates to the
genetic medicines community. We have dramatically reduced the time,
cost, and development risk of creating extrahepatic delivery
vehicles that will liberate patients from genetic diseases.”
Key Highlights from the Presentation:
Liberate Bio has built a robust nanoparticle screening platform
for evaluating and identifying extrahepatic delivery vehicles
directly in non-human primates (NHPs) – RAPTOR™. RAPTOR™ combines
the power of high throughput screening with artificial intelligence
to efficiently explore vast design spaces covering lipid chemistry,
formulation characteristics, and targeting approaches. RAPTOR™ has
identified lead candidates with enrichment in bone marrow, spleen,
and cardiac tissue from a diverse library of more than 150 LNPs
across multiple structural and chemically distinct classes of
ionizable lipids.
TIDES Presentation Details:
TITLE: “RAPTOR: A High Throughput Platform for Screening LNPs in
Primates” SESSION TITLE: Delivery of Macromolecules PRESENTATION
TYPE: Oral PRESENTER: Walter R. Strapps, PhD, Chief Scientific
Officer, Liberate Bio DATE AND TIME: Thursday, May 16, 2024, from
4:45 p.m. – 5:15 p.m. ET
About Liberate Bio
Our vision at Liberate Bio is to achieve the
extraordinary—delivering genetic medicines that transcend
liver-based limitations, liberating patients from disease. Today’s
genetic medicines are limited by the availability of safe,
effective delivery vehicles that direct nucleic acid therapeutics
to any organ other than the liver. To realize the full potential of
genetic medicines, we use our proprietary screening platform to
rapidly evaluate rational and artificial intelligence-designed
nanoparticles, reducing the cycle time for identifying novel
vehicles from years to months. We have built the team and a suite
of tools that allows us to rapidly move RNA therapeutics to the
clinic by significantly increasing the translatability of the
preclinical work.
For more information about the company’s technologies, team, and
mission, visit www.liberatebio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516399156/en/
Mariesa Kemble KembleM@mac.com 608-850-4745